Thai FDA Approves New Oral Antibiotic Nuzolvence for Gonorrhoea
Thailand's Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for uncomplicated urogenital gonorrhoea, making it the second country after the United States to authorize the drug. Dr. Reddy's Laboratories led the priority review submission with support from the GARDP Foundation, while its subsidiary Aurigene Pharmaceutical Services contributed to product development. The drug was developed through a public-private partnership involving Innoviva Specialty Therapeutics. GARDP holds rights to register and commercialize zoliflodacin in over 75% of countries, including most low- and middle-income nations, while Innoviva retains commercial rights in major markets like North America and the EU. The approval highlights collaboration among global health organizations and pharmaceutical companies to address multidrug-resistant gonorrhoea.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection